Boulding Mark Elliott
PTC Therapeutics, Inc. · EXEC. VP AND CLO
Boulding Mark Elliott is listed in filings as EXEC. VP AND CLO at PTC Therapeutics, Inc.. This profile follows SEC Form 4 activity through May 19, 2026, including sale activity. Recent filings connect the profile to PTC Therapeutics, Inc. (PTCT). The current snapshot covers public activity from Oct 7, 2025 to May 19, 2026. Reported amounts are shown as $169.8K to $33.1K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.
Latest Trades
| Company | Value | Action | Price | Last Price |
|---|---|---|---|---|
| $170k2.4k shares | SellMay 15, 2026 | $72.08 | $78.52 | |
| $33k456 shares | SellMay 15, 2026 | $72.67 | $78.52 |